Clinical trials: Neurodegenerative Diseases
Parkinson s Disease
Comparison of Immersive and Non-Immersive Virtual Reality Rehabilitation in Parkinson's Disease
Parkinson's disease commonly affects walking ability, balance, mobility, and cognitive function, increasing the risk of falls and reducing independence.
- Trial name
- VR-PD (NCT07659288)
- Testing
- Immersive Virtual Reality, Non-Immersive Virtual Reality
- Where
- Chile
- Volunteers
- 16 people
- Sponsor
- Neuro Group XR Inc.
Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects
This study is designed as a single ascending dose study in healthy subjects to evaluate safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) in plasma and Cerebrospinal (CSF) following single oral doses of E2212.
- Trial name
- NCT01221259
- Testing
- E2212
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Friedreich Ataxia
A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants
This purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of DT-216P2 administered either subcutaneously (SC) and intravenously (IV) in normal healthy participants.
- Trial name
- NCT06772870
- Testing
- DT-216P2, Saline
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Design Therapeutics, Inc.
Dementia Alzheimer's Type
Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Primary Objective: To compare the effect of repeat doses of Leukine to placebo administered subcutaneously (SC) on established cortical amyloid load in patients with mild cognitive impairment (MCI) due to Alzheimer's disease…
- Trial name
- NCT02667496
- Testing
- Sargramostim GZ402664, Florbetapir F18
- Where
- United States
- Sponsor
- Sanofi
Myasthenia Gravis
Myasthenia Gravis Inebilizumab Trial
Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.
- Trial name
- MINT (NCT04524273)
- Testing
- inebilizumab
- Where
- 104 sites in United States, Argentina and 17 more
- Volunteers
- 238 people
- Sponsor
- Amgen
Parkinson Disease
Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics
The purpose of the study was to To investigate whether the administration of BIA 6-512 (25 mg, 50 mg, 75 mg and 100 mg) at steady-state affects the pharmacokinetics of levodopa when administered in combination with a single-dose…
- Trial name
- NCT03094156
- Testing
- BIA 6-512, Madopar® 250, Comtan®
- Where
- Portugal
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Electromyography Signals as Biomarkers for Parkinson's Disease
A simple, painless and reliable method to detect Parkinson's disease at an early stage is very important to patients, doctors and researchers.
- Trial name
- NCT02168504
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Norconnect Inc
Amyotrophic Lateral Sclerosis, Fasciculation
Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS
The FLX-787-106 study will determine how well FLX-787-ODT works to reduce fasciculations in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03338114
- Testing
- FLX-787-ODT (orally disintigrating tablet)
- Where
- United States
- Sponsor
- Flex Pharma, Inc.
Healthy Volunteers
A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b in healthy subjects.
- Trial name
- NCT04208152
- Testing
- anle138b
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Alzheimer's Disease, Dementia
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia
The objective of the study is to define the performance of blood-based signatures for Alzheimer's Disease (AD) in different patients populations including AD, non-AD dementia, and non-demented controls.
- Trial name
- NCT00880347
- Testing
- Blood sampling
- Where
- 21 sites in France
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Exonhit
Huntington Disease
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their…
- Trial name
- NCT06667414
- Where
- 45 sites in United States, Argentina and 10 more
- Volunteers
- 574 people
- Sponsor
- Hoffmann-La Roche
Tourette's Disorder
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)
The goal of the current trial is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01418352
- Testing
- Aripiprazole
- Where
- 35 sites in United States, Bulgaria and 3 more
- Volunteers
- 83 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Disease
Effects of ONO-2506PO in Patients With Alzheimer's Disease
The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.
- Trial name
- NCT00083421
- Testing
- ONO-2506PO
- Where
- 87 sites in United States, Canada
- Volunteers
- 647 people
- Sponsor
- Ono Pharma USA Inc
Lennox Gastaut Syndrome, Dravet Syndrome
Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
This is a prospective, observational study on approximately 70-100 Real World participants affected by LGS, DS, or TSC treated with Epidyolex® as prescribed in the summary of product characteristics.
- Conditions
- Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
- Trial name
- EpiTALY (NCT05485831)
- Testing
- Epidiolex 100 mg/mL Oral Solution
- Where
- 18 sites in Italy
- Volunteers
- 111 people
- Sponsor
- Jazz Pharmaceuticals
Alzheimer Disease
Evaluation of Galantamine in the Treatment of Alzheimer's Disease
Galantamine is an experimental drug being evaluated in the United States for the treatment of Alzheimer's disease. Results from previous clinical trials suggest that galantamine may improve cognitive performance in individuals…
- Trial name
- NCT00000172
- Testing
- Galantamine
- Where
- 55 sites in United States
- Sponsor
- Janssen, LP
Parkinson Disease
Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)
Evaluate the Safety and Effectiveness of Staged Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD).
- Trial name
- NCT04728295
- Testing
- Exablate 4000
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 50 people
- Sponsor
- InSightec
Stroke, Parkinson Disease
Videofluoroscopic Swallowing Study (VFSS)
The study procedure of simultaneous VFSS and DDS measurement will be completed in one day and the subject will be followed within 2 business days after the study procedure to monitor for adverse events.
- Conditions
- Stroke, Parkinson Disease, Multiple Sclerosis, Oropharyngeal Dysphagia
- Trial name
- PORSCHE (NCT03387267)
- Testing
- Dysphagia Detection System
- Where
- 13 sites in United States, Finland
- Volunteers
- 452 people
- Sponsor
- Société des Produits Nestlé (SPN)
Parkinson Disease
Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease
This clinical trial focus on the delivery of Cerezyme® in Parkinson's Disease (PD) patients using MR-guided focused ultrasound (MRgFUS) induced opening of the blood-brain barrier (BBB).
- Trial name
- NCT04370665
- Testing
- Exablate BBBD with Cerezyme
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- InSightec
Parkinson's Disease
A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.
The purpose of this study is to assess the safety and tolerability of a dose of 95μg sNN0031 after intracerebroventricular administration to patients with Parkinson's disease
- Trial name
- NCT01829867
- Testing
- sNN0031
- Where
- 2 sites in Sweden
- Volunteers
- 5 people
- Sponsor
- Newron Sweden AB
Parkinson's Disease
A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease
The purpose of this clinical trial is to compare the safety and tolerability of two dose regimens of fipamezole in adult patients with Parkinson's Disease who are receiving levodopa.
- Trial name
- Fipamezole (NCT01149811)
- Testing
- Fipamezole ODT, Fipamezole ODT Cohort 2
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Bausch Health Americas, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.